JP2010520306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520306A5 JP2010520306A5 JP2009552881A JP2009552881A JP2010520306A5 JP 2010520306 A5 JP2010520306 A5 JP 2010520306A5 JP 2009552881 A JP2009552881 A JP 2009552881A JP 2009552881 A JP2009552881 A JP 2009552881A JP 2010520306 A5 JP2010520306 A5 JP 2010520306A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disease
- pharmaceutical formulation
- pharmaceutical
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 claims 5
- 101710205336 Steroid hormone receptor ERR1 Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 210000000845 cartilage Anatomy 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940125425 inverse agonist Drugs 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000025940 Back injury Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 229940124802 CB1 antagonist Drugs 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 102000030595 Glucokinase Human genes 0.000 claims 1
- 108010021582 Glucokinase Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000022159 cartilage development Effects 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000019439 energy homeostasis Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000407 monoamine reuptake Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 1
- 229960001243 orlistat Drugs 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims 1
- 229960003015 rimonabant Drugs 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 *c(c(*)c1*)ccc1Oc1ccc(C=C(*C(N2)=O)C2=O)cc1* Chemical compound *c(c(*)c1*)ccc1Oc1ccc(C=C(*C(N2)=O)C2=O)cc1* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89345307P | 2007-03-07 | 2007-03-07 | |
| PCT/US2008/056004 WO2008109727A1 (en) | 2007-03-07 | 2008-03-06 | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520306A JP2010520306A (ja) | 2010-06-10 |
| JP2010520306A5 true JP2010520306A5 (OSRAM) | 2011-03-24 |
Family
ID=39535719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552881A Pending JP2010520306A (ja) | 2007-03-07 | 2008-03-06 | エストロゲン関連受容体−αモジュレーターとしての置換フェノキシチアゾリジンジオン |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7846953B2 (OSRAM) |
| EP (1) | EP2129668A1 (OSRAM) |
| JP (1) | JP2010520306A (OSRAM) |
| KR (1) | KR20090127410A (OSRAM) |
| CN (1) | CN101679322A (OSRAM) |
| AR (1) | AR065655A1 (OSRAM) |
| AU (1) | AU2008222745A1 (OSRAM) |
| BR (1) | BRPI0808445A2 (OSRAM) |
| CA (1) | CA2679944A1 (OSRAM) |
| CL (1) | CL2008000670A1 (OSRAM) |
| CO (1) | CO6231008A2 (OSRAM) |
| EA (1) | EA200970837A1 (OSRAM) |
| EC (1) | ECSP099614A (OSRAM) |
| IL (1) | IL200757A0 (OSRAM) |
| MX (1) | MX2009009517A (OSRAM) |
| NI (1) | NI200900163A (OSRAM) |
| NZ (1) | NZ579372A (OSRAM) |
| SV (1) | SV2009003367A (OSRAM) |
| TW (1) | TW200902508A (OSRAM) |
| UA (1) | UA98485C2 (OSRAM) |
| WO (1) | WO2008109727A1 (OSRAM) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| EA200970837A1 (ru) * | 2007-03-07 | 2010-04-30 | Янссен Фармацевтика Н.В. | ЗАМЕЩЁННЫЕ ФЕНОКСИТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ α-РЕЦЕПТОРА ЭСТРОГЕНА |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| AU2008297877C1 (en) | 2007-09-14 | 2013-11-07 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones |
| KR20100065191A (ko) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온 |
| DE602008004794D1 (de) | 2007-09-14 | 2011-03-10 | Addex Pharmaceuticals Sa | 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one |
| US8785486B2 (en) | 2007-11-14 | 2014-07-22 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| CN102186477B (zh) | 2008-10-16 | 2013-07-17 | 奥梅-杨森制药有限公司 | 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物 |
| CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
| US8637558B2 (en) * | 2008-12-30 | 2014-01-28 | Industry-Academic Cooperation Foundation, Chosun University | Thiazolidinedione derivative and use thereof |
| WO2010118324A2 (en) | 2009-04-09 | 2010-10-14 | Nuclea Biotechnologies, LLC | Antibodies against fatty acid synthase |
| AR076861A1 (es) | 2009-05-12 | 2011-07-13 | Addex Pharma Sa | Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2 |
| WO2010130422A1 (en) | 2009-05-12 | 2010-11-18 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2010135468A1 (en) * | 2009-05-19 | 2010-11-25 | Vivia Biotech S.L. | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| US8187871B2 (en) * | 2009-08-11 | 2012-05-29 | Janssen Pharmaceutica N.V. | Co-crystallization of ERR-α with a ligand that forms a reversible covalent bond |
| WO2011019558A1 (en) * | 2009-08-11 | 2011-02-17 | Janssen Pharmaceutica Nv | Methods to measure dissociation rates for ligands that form reversible covalent bonds |
| WO2011031517A1 (en) | 2009-08-27 | 2011-03-17 | Nuclea Biotechnologies, LLC | Method and assay for determining fas expression |
| EP2488027A4 (en) * | 2009-10-09 | 2013-04-17 | Univ Ohio State Res Found | THIAZOLIDINDIONENERGIERESTRIKTIONSMIMETIKA |
| ES2565487T3 (es) * | 2010-07-28 | 2016-04-05 | Orchid Chemicals And Pharmaceuticals Ltd | Compuestos de difeniléter para su uso en el tratamiento de enfermedades hepáticas |
| US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| WO2012140300A1 (es) * | 2011-04-11 | 2012-10-18 | Servicio Andaluz De Salud | Compuestos y composiciones para el tratamiento de mieloma múltiple |
| ES2390303B1 (es) * | 2011-04-11 | 2013-09-16 | Servicio Andaluz De Salud | Compuestos y composiciones para el tratamiento de mieloma múltiple. |
| USD688465S1 (en) | 2011-06-14 | 2013-08-27 | Telebrands Corp. | Hair detangler |
| WO2013018929A1 (en) | 2011-08-04 | 2013-02-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| NZ700872A (en) | 2012-03-26 | 2016-09-30 | Nippon Chemiphar Co | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| KR20220000993A (ko) | 2013-09-25 | 2022-01-04 | 닛뽕 케미파 가부시키가이샤 | 골·연부에 발생하는 거세포성 종양, 연골육종 또는 골육종의 예방, 치료 또는 전이 예방을 위한 약제, 동맥색전술용 국소 주입제 및 인공골 |
| PH12019500127B1 (en) | 2014-01-21 | 2022-05-04 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| SMT201900545T1 (it) | 2014-01-21 | 2019-11-13 | Janssen Pharmaceutica Nv | Combinazioni comprendenti modulatori allosterici positivi o agonisti ortosterici del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| CA2972065A1 (en) | 2014-12-23 | 2016-06-30 | Intellectual Property Associates, Llc | Methods and formulations for transdermal administration |
| EP3370715A4 (en) | 2015-11-02 | 2019-05-15 | Yale University | CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| EP3681479B1 (en) | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| UA129204C2 (uk) | 2019-07-04 | 2025-02-05 | Лід Фарма Голдінґ Б.В. | МОДУЛЯТОРИ АЛЬФА-РЕЦЕПТОРА, ПОВ'ЯЗАНОГО З ЕСТРОГЕНОМ (ERR<font face="Symbol">a</font>) |
| CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
| MX2022004394A (es) * | 2019-10-18 | 2022-05-18 | Lead Pharma Holding Bv | Moduladores de receptor alfa relacionado con estrogenos (erra). |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037842A (en) | 1990-06-05 | 1991-08-06 | Pfizer Inc. | Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents |
| JPH09176162A (ja) * | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
| JP2001072592A (ja) | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| US20060014812A1 (en) | 2004-07-14 | 2006-01-19 | Player Mark R | Use of estrogen related receptor-modulating aryl ethers |
| WO2006047269A2 (en) | 2004-10-22 | 2006-05-04 | Exelixis, Inc. | Pharmaceutical compositions |
| CL2008000669A1 (es) * | 2007-03-07 | 2008-11-03 | Janssen Pharmaceutica Nv | Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras. |
| EA200970837A1 (ru) * | 2007-03-07 | 2010-04-30 | Янссен Фармацевтика Н.В. | ЗАМЕЩЁННЫЕ ФЕНОКСИТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ α-РЕЦЕПТОРА ЭСТРОГЕНА |
-
2008
- 2008-03-06 EA EA200970837A patent/EA200970837A1/ru unknown
- 2008-03-06 CA CA002679944A patent/CA2679944A1/en not_active Abandoned
- 2008-03-06 TW TW097107941A patent/TW200902508A/zh unknown
- 2008-03-06 BR BRPI0808445-9A patent/BRPI0808445A2/pt not_active IP Right Cessation
- 2008-03-06 KR KR1020097020449A patent/KR20090127410A/ko not_active Withdrawn
- 2008-03-06 CN CN200880015196A patent/CN101679322A/zh active Pending
- 2008-03-06 EP EP08731504A patent/EP2129668A1/en not_active Ceased
- 2008-03-06 WO PCT/US2008/056004 patent/WO2008109727A1/en not_active Ceased
- 2008-03-06 MX MX2009009517A patent/MX2009009517A/es active IP Right Grant
- 2008-03-06 UA UAA200910123A patent/UA98485C2/ru unknown
- 2008-03-06 AU AU2008222745A patent/AU2008222745A1/en not_active Abandoned
- 2008-03-06 CL CL2008000670A patent/CL2008000670A1/es unknown
- 2008-03-06 JP JP2009552881A patent/JP2010520306A/ja active Pending
- 2008-03-06 NZ NZ579372A patent/NZ579372A/en not_active IP Right Cessation
- 2008-03-06 US US12/043,269 patent/US7846953B2/en not_active Expired - Fee Related
- 2008-03-07 AR ARP080100962A patent/AR065655A1/es not_active Application Discontinuation
-
2009
- 2009-09-04 NI NI200900163A patent/NI200900163A/es unknown
- 2009-09-06 IL IL200757A patent/IL200757A0/en unknown
- 2009-09-07 EC EC2009009614A patent/ECSP099614A/es unknown
- 2009-09-07 SV SV2009003367A patent/SV2009003367A/es unknown
- 2009-09-11 CO CO09097934A patent/CO6231008A2/es not_active Application Discontinuation
-
2010
- 2010-10-07 US US12/899,812 patent/US8344009B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520306A5 (OSRAM) | ||
| JP2010520308A5 (OSRAM) | ||
| JP2010520307A5 (OSRAM) | ||
| HRP20120160T1 (hr) | Supstituirani fenoksi n-alkilirani tiazoldindion kao modulatori estrogen srodnih alfa-receptora | |
| JP2007508361A5 (OSRAM) | ||
| JP2012525393A5 (OSRAM) | ||
| JP2018535967A5 (OSRAM) | ||
| JP2004514663A5 (OSRAM) | ||
| JP2012504133A5 (OSRAM) | ||
| JP2011051993A5 (OSRAM) | ||
| JP2013519632A5 (OSRAM) | ||
| JP2020502111A5 (OSRAM) | ||
| JP2011513410A5 (OSRAM) | ||
| JP2020506951A5 (OSRAM) | ||
| JP2005505538A5 (OSRAM) | ||
| JP2009506119A5 (OSRAM) | ||
| JP2011509309A5 (OSRAM) | ||
| JP2004511466A5 (OSRAM) | ||
| JP2008195730A5 (OSRAM) | ||
| JP2010501584A5 (OSRAM) | ||
| JP2010504344A5 (OSRAM) | ||
| JP2014502641A5 (OSRAM) | ||
| JP2008521827A5 (OSRAM) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2014505107A5 (OSRAM) |